Author: Ken Dropiewski

Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter

Rhythm by Comments are Disabled

ST. LOUIS, Jan. 27, 2025 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received European CE Mark approval for the MAGiC™ ablation catheter. This approval is a significant milestone for Stereotaxis and for the community of physicians pioneering robotics in electrophysiology. It is reflective of the company’s commitment to advancing significant innovations that make robotics increasingly impactful across interventional medicine.

Continue Reading →

MedStar Health First in Maryland to Implant FDA Approved Tricuspid Valves in Patients Without Need for Open Heart Surgery

Coronary/Structural Heart by Comments are Disabled

Two patients at MedStar Union Memorial Hospital receive recently FDA-approved Evoque Tricuspid Valve Replacements for severe tricuspid regurgitation. BALTIMORE, Jan. 24, 2025 /PRNewswire/ — In two separate procedures, MedStar Health cardiac experts at MedStar Union Memorial Hospital…

Continue Reading →

Positron Corporation Secures Agreement to Sell and Rent Eight NeuSight PET-CT Scanners

Financial by Comments are Disabled

Niagara Falls, NY, Jan. 24, 2025 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company specializing in PET and PET-CT imaging systems and clinical services, is pleased to announce the sale of four and rental of four NeuSight PET-CT 64-slice scanners to a prominent, established provider of advanced diagnostics and treatment for cardiovascular disease. This achievement highlights Positron’s commitment to providing innovative imaging solutions that enable healthcare providers to elevate patient care and achieve superior clinical outcomes.

Continue Reading →

VANTIS VASCULAR ANNOUNCES SUPERIOR CLINICAL PERFORMANCE OF THE CROSSFAST ADVANCED DELIVERY SYSTEM IN FIRST COMMERCIAL CASES

Coronary/Structural Heart by Comments are Disabled

CrossFAST performance exceeded expectations in ten complex high-risk coronary interventions SAN JOSE, Calif., Jan. 23, 2025 /PRNewswire/ — Vantis Vascular, Inc., a pioneering medical technology company founded by physicians with a passion to revolutionize vascular interventions, today…

Continue Reading →

Conavi Medical Provides Shareholder Update and 2025 Outlook

Financial by Comments are Disabled

– U.S. FDA 510(k) filing of next-generation Novasight system targeted for H2 2025 with U.S. commercial launch planned for early 2026- Evolving medical guidelines position next-generation Novasight system as new imaging standard in interventional cardiology- Multiple non-dilutive opportunities being pursued to fund growth TORONTO, Jan. 23, 2025 (GLOBE NEWSWIRE) — To our Shareholders, As we…

Continue Reading →

Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics’ novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with Atrial Fibrillation

Rhythm by Comments are Disabled

Secondary endpoints also showed a highly significant 67% reduction in major bleeding and an 89% reduction in gastrointestinal (GI) bleeding The company’s AZALEA-TIMI 71 study is the longest head-to-head study of a Factor XI inhibitor vs. a direct oral anticoagulant (DOAC) CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) — Anthos Therapeutics, Inc., a transformative, clinical-stage…

Continue Reading →

Johnson & Johnson Reports Q4 and Full-Year 2024 Results

Financial by 0 comments

January 22, 2025 06:20 AM Eastern Standard Time NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024. “2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in innovation,” said Joaquin Duato, Chairman […]

Continue Reading →

CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025

Financial by Comments are Disabled

MINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2024 financial and operating results after market close on Tuesday, February…

Continue Reading →

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium

Rhythm by 0 comments

MIAMI–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late-breaking data from its Nanosecond PFA 360° Cardiac Catheter System first-in-human feasibility study, which data were recently presented at the 30th Annual AF Symposium 2025 meeting. “This novel technology […]

Continue Reading →
1 … 34 35 36 37 38 … 1,196